Effects of estrogen replacement on the progression of coronary-artery atherosclerosis

New England Journal of Medicine

Volumn 343, Issue 8, 2000, Pages 522-529

  Herrington, David M ^a   Reboussin, David M ^a   Brosnihan, K Bridget ^a   Sharp, Penny C ^a   Shumaker, Sally A ^a   Snyder, Thomas E ^a   Furberg, Curt D ^a   Kowalchuk, Glen J ^b   Stuckey, Thomas D ^c   Rogers, William J ^d   Givens, David H ^e   Waters, David ^f  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

^c LeBauer Cardiovascular Research Foundation   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e Winston Salem University   (United States)

^f SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; POSTMENOPAUSE; TRIGLYCERIDES;

EID: 0034710627     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200008243430801     Document Type: Article

References (34)

1. National Cholesterol Education Program: Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
2. Preventing heart attack and death in patients with coronary disease
3. Guide to primary prevention of cardiovascular diseases: A statement for healthcare professionals from the Task Force on Risk Reduction
4. Hormone therapy to prevent disease and prolong life in postmenopausal women
5. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
6. The protective effects of estrogen on the cardiovascular system
7. How do we explain the clinical benefits of estrogen? From bedside to bench
8. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
9. Lessons from HERS: The null and beyond
10. Hormone replacement therapy for secondary prevention of coronary heart disease
11. Cardioprotection for the postmenopausal women: HERS results and their implications
12. The HERS trial results: Paradigms lost?
13. The Estrogen Replacement and Atherosclerosis (ERA) study: Study design and baseline characteristics of the cohort
14. The Heart and Estrogen/progestin Replacement Study (HERS): Design, methods, and baseline characteristics
15. Regression of atherosclerosis in female monkeys
16. Coronary artery quantitation and data management system for paired cineangiograms
17. Hypolipidemic intervention and plaque stabilization
18. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial
19. Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: A 10-year Familial Atherosclerosis Treatment Study (FATS) follow-up
20. Progression of coronary artery disease predicts clinical coronary events: Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study
21. Prognostic significance of progression of coronary atherosclerosis
22. Changes in sequential coronary arteriograms and subsequent coronary events
23. Effects of estrogen on the anatomic and functional sequelae of coronary atherosclerosis
24. Hormone replacement therapy and increased plasma concentration of C-reactive protein
25. Hormone replacement therapy, inflammation, and hemostasis in elderly women
26. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study
27. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women
28. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
29. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: Lack of an effect of added progesterone
30. Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterolfed rabbits
31. Effect of 17-beta estradiol on pre-existing atherosclerotic lesions: Role of the endothelium
32. The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium: A time course study in cholesterol-clamped rabbits
33. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease
34. Design of the Women's Health Initiative clinical trial and observational study